GW Pharmaceuticals plc products

GW is committed to developing new medicines to treat rare, treatment-resistant epilepsy conditions where there are limited or in some cases, no approved treatment options.

Sativex^® (delta-9-tetrahydrocannibinol and cannabidiol in the EU; nabiximols in the US) is an oromucosal spray of a formulated cannabis extract that contains the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD), as well as specific minor cannabinoids and other non-cannabinoid components. We developed Sativex^® to be administered as an oromucosal spray, whereby the active ingredients are absorbed in the lining of the mouth, either under the tongue or inside the cheek. Regulatory approval has been obtained in numerous countries outside the United States for the treatment of spasticity (muscle stiffness/spasm) due to multiple sclerosis (MS).

Sativex^® (nabiximols) has been developed as a treatment for the relief of symptoms in patients with moderate to severe spasticity due to multiple sclerosis (MS) that has not been adequately treated with currently used therapies.  Sativex^® is not approved in all countries.  Please consult with your doctor if you would like more information.

The discovery of the cannabinoid receptors led to the demonstration of the existence of the body’s own natural cannabinoids  endocannabinoids), the most important of which are arachidonoyl-ethanolamide (anandamide), 2-arachidonoyl glycerol (2-AG) and arachidonyl glyceryl ether (noladin ether). This remains a highly dynamic field.

Naturally occurring cannabis contains a group of chemical compounds not found in other plants known as cannabinoids. Over 80 different cannabinoids have so far been identified but the role and importance of many of these has yet to be fully understood. GW is researching a large number of cannabinoids, each of which has different effects and applications.